Earnings Call · Q4 FY2021·2022-02-24

Q4 21EPS +25.71%·Rev n/aQ3 21EPS 0.00%·Rev n/aQ2 21EPS -6.45%·Rev n/aQ1 21EPS -10.34%·Rev n/a⚠ consensus missing

SANGAMO THERAPEUTICS, INC SGMO

Aron Feingold — Head of Investor Relations

Sandy Macrae — Chief Executive Officer

Rob Schott — Senior Vice President, Clinical Development

Prathyusha Duraibabu — Chief Financial Officer

+6.4%1d on move date+4.9% vs SPY3d+2.3%5d+6.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SGMO calls or request research access.

More SGMO calls Browse calls Request research access